Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced preclinical data characterizing JADE301, its potentially best-in-class, half-life-extended anti-interferon beta (IFN-β) monoclonal antibody in development for dermatomyositis (DM), a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and progressive muscle weakness. JADE301 is a fully human IgG1 monoclonal antibody with a YTE modification designed to selectively and potently neutralize IFN-β and inhibit downstream signaling implicated as a proximal driver in DM pathogenesis.